Rezolute - RZLT Total Company Value-to-Revenue Ratio

rezolutebio.com (RZLT) - corporate logo

Rezolute, Inc. (RZLT) develops unique treatments for rare endocrine pathologies, including the drug RZ358. The company aims to secure a monopoly position within the orphan drug niche for hyperinsulinism. Anticipation of final Phase 3 trial data is driving the price action. The EV/Revenue multiple demonstrates financial stability excluding debt, with the current value standing at 0.00, helping to avoid overpaying for the asset.

RZLT Rezolute, Inc.: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

rezolutebio.com - analytical breakdowns and key metrics (RZLT)

- share price and expert price forecast:
Fundamental valuation:rezolutebio.com
Product sample of Rezolute, Inc.

This indicator reflects the enterprise value (EV) minus net debt per unit of revenue, measuring the market premium paid for every dollar of current sales. For the biotech company Rezolute, Inc. (RZLT), the Enterprise Value to Sales ratio is currently secondary due to the stage of clinical trials. Analyzing the chart, an investor assesses the potential for future monopoly margins following drug approval. An increasing multiple confirms market confidence in the scalability of the molecules.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|EV/Sales Multiple LXRX|Total Company Value-to-Revenue Ratio MBX Corp|Altimmune Pharma - Company Value to Revenue|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)